ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $3.05.

ALXO has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. HC Wainwright dropped their price objective on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, January 24th. UBS Group reduced their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research note on Monday, January 27th. Finally, Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $12.00 to $2.00 in a research note on Thursday, December 19th.

ALX Oncology Stock Performance

ALXO opened at $1.10 on Tuesday. ALX Oncology has a 12-month low of $0.96 and a 12-month high of $17.83. The firm has a market capitalization of $58.01 million, a P/E ratio of -0.37 and a beta of 0.96. The stock’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.81. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Activity at ALX Oncology

In related news, Director Rekha Hemrajani purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 14,443 shares of company stock valued at $23,309 over the last quarter. 33.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. JSF Financial LLC bought a new stake in shares of ALX Oncology in the 4th quarter worth about $29,000. SG Americas Securities LLC grew its stake in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of ALX Oncology during the third quarter worth approximately $88,000. Sei Investments Co. bought a new position in shares of ALX Oncology in the fourth quarter valued at approximately $102,000. Finally, Barclays PLC boosted its holdings in shares of ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares in the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.